Antibody-mediated immunity against tuberculosis: Implications for vaccine development

Jacqueline M. Achkar; Arturo Casadevall

doi:10.1016/j.chom.2013.02.009

Antibody-mediated immunity against tuberculosis: Implications for vaccine development

Jacqueline M. Achkar
, Arturo Casadevall

Research output: Contribution to journal › Review article › peer-review

166 Scopus citations

Abstract

There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.

Original language	English (US)
Pages (from-to)	250-262
Number of pages	13
Journal	Cell Host and Microbe
Volume	13
Issue number	3
DOIs	https://doi.org/10.1016/j.chom.2013.02.009
State	Published - Mar 13 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Parasitology
Microbiology
Virology

Access to Document

10.1016/j.chom.2013.02.009

Cite this

@article{874cad6cebfc4e0f81ddbf16f3f8a5b3,

title = "Antibody-mediated immunity against tuberculosis: Implications for vaccine development",

abstract = "There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.",

author = "Achkar, \{Jacqueline M.\} and Arturo Casadevall",

note = "Funding Information: This work was supported by funds from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; AI-067665 to J.M.A. and AI-033774, AI-052733, AI-033142 to A.C.); the National Heart, Lung, and Blood Institute (NHLBI; HL-059842 to A.C.); the Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine (AI-51519; J.M.A.); the Aeras TB Vaccine Foundation (J.M.A. and A.C.); and the Food and Drug Administration (FDA; 1U18 FD004012/01 to J.M.A.). A.C. is also the recipient of a Bill and Melinda Gates Grand Challenge award and a TB Vaccine Accelerator Program award. We thank Anke Ziegenbalg for her graphic assistance with the figure.",

year = "2013",

month = mar,

day = "13",

doi = "10.1016/j.chom.2013.02.009",

language = "English (US)",

volume = "13",

pages = "250--262",

journal = "Cell Host and Microbe",

issn = "1931-3128",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Antibody-mediated immunity against tuberculosis

T2 - Implications for vaccine development

AU - Achkar, Jacqueline M.

AU - Casadevall, Arturo

N1 - Funding Information: This work was supported by funds from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; AI-067665 to J.M.A. and AI-033774, AI-052733, AI-033142 to A.C.); the National Heart, Lung, and Blood Institute (NHLBI; HL-059842 to A.C.); the Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine (AI-51519; J.M.A.); the Aeras TB Vaccine Foundation (J.M.A. and A.C.); and the Food and Drug Administration (FDA; 1U18 FD004012/01 to J.M.A.). A.C. is also the recipient of a Bill and Melinda Gates Grand Challenge award and a TB Vaccine Accelerator Program award. We thank Anke Ziegenbalg for her graphic assistance with the figure.

PY - 2013/3/13

Y1 - 2013/3/13

N2 - There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.

AB - There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.

UR - https://www.scopus.com/pages/publications/84875141413

UR - https://www.scopus.com/pages/publications/84875141413#tab=citedBy

U2 - 10.1016/j.chom.2013.02.009

DO - 10.1016/j.chom.2013.02.009

M3 - Review article

C2 - 23498951

AN - SCOPUS:84875141413

SN - 1931-3128

VL - 13

SP - 250

EP - 262

JO - Cell Host and Microbe

JF - Cell Host and Microbe

IS - 3

ER -

Antibody-mediated immunity against tuberculosis: Implications for vaccine development

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this